Features of the arterial hypertension clinical course in patients with ischemic heart disease and atrial fibrillation.

Authors

  • M. I. Yalovenko
  • O. O. Khaniukov

DOI:

https://doi.org/10.26641/2307-0404.2018.4.153005

Keywords:

arterial hypertension, atrial fibrillation, ischemic heart disease

Abstract

More than 30% of the world's population suffer from arterial hypertension (AH). AH is one of the important cardiovascular risk factors. AH is associated with a 1.5-fold increase in the risk of atrial fibrillation (AF). AF is the most common cardiac arrhythmias in the population. Nowadays, AF is regarded as potentially lethal arrhythmia, in consideration of the broad range of its negative consequences not only due to significant deterioration in the quality of the patients’ life but also due to related significant increase in the incidence of serious complications and death. Objective: to study the features of the AH clinical course, the nature of the target organs lesion in patients with ischemic heart disease with and without permanent form of atrial fibrillation. The study included 78 patients, average age was 66,3±1,0, men – 43 (55,1%). Patients were divided into 2 groups: group 1 (n=42) consisted of patients with AH, IHD and permanent AF; group 2 (n=36) included patients with AH and IHD without heart rhythm disturbances. The analysis of the frequency of lesions of target organs in groups 1 and 2 showed that the III degree of hypertension was detected in 25 (59,5%) patients in group 1 and in 8 (22,2%) patients in group 2. Degree III was diagnosed in 17 (40,5%) and 24 (66,6%) patients of 1-st and 2-nd groups, respectively. Absence of targets organ damage in group 2 was documented in 4 (11,1%) patients. AF presence is associated with a severe course of hypertension and more frequent lesion of target organs. Based on the research results, it was established a direct relation between the duration of AH and the duration of the permanent form of AF. It is expedient for patients with AF arisen against the background of AH to achieve target levels of BP for prevention disease progression and improving the prognosis.

Author Biographies

M. I. Yalovenko

SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»
Department of Internal Medicine 3
V. Vernadsky str., 9, Dnipro, 49044, Ukraine

O. O. Khaniukov

SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»
Department of Internal Medicine 3
V. Vernadsky str., 9, Dnipro, 49044, Ukraine

References

Dzyak GV, Zharіnov OY. [Atrial fibtillation]. Chet­verta khvilia. 2011;192. Ukrainian.

Zharіnov OY, Talayeva TV, Lіshchishina OM, et al. [Diagnosis and treatment of atrial fibrillation]. Recom­mendations of the Working Group on Heart Rhythm Disorders of the Association of Cardiologists ofUkraine. 2014;134. Ukrainian.

Ivanov VP, Danilevich TD. [The role of aldoste­rone in the development of atrial fibrillation, the antial­dosterone concept of upstream therapy]. Kardiologiia, ot nauki k praktike. 2016;1:89-101. Ukrainian.

Mitchenko OІ, Romanov VYu. [Optimization and treatment and correction of cardiovascular risk in patients with arterial hypertension and metabolic syndrome]. Ukrainskyi medychnyi chasopys. 2015;2(106):67-70. Ukrainian.

[Order of HM ofUkrainedated 25.05.2012 N 384. On Approval and implementation of medical-technological documents on standardization of medical assistance in arterial hypertension]. Kyiv; 2012. Ukrainian.

[Order of HM ofUkrainedated 02.03.2016 N 152. On Approval and implementation of medical-techno­logical documents on standardization of medical assistance in the case of stable ischemic heart disease ]. Kyiv; 2016. Ukrainian.

[Order of HM ofUkrainedated 15.06.2016 N 597. On approval and implementation of medical-technological documents on standardization of medical care at atrial fibrillation]. Kyiv; 2016. Ukrainian.

Rebrova OJu. [Statistical analysis of medical data. Application of software package STATISTICA]. Moskva, Mediasphera. 2002;312. Russian.

Fushtey IM, Goldіvskiy BM, Sіd EV. [Inflam­ma­tory activation in patients with atrial fibrillation]. Medytsyna nevіdkladnykh stanіv. 2012;2(41):34-38. Ukrainian.

Khaniukov OO. [Dynamics of levels of C-reactive protein and interleukins of plasma on the back­ground of complex medical treatment of patients with multifocal atherosclerosis and diabetes mellitus]. Medicni perspektivi. 2012;3:36-42. Ukrainian.

Camm AJ, Kirchhof P, Lip GY, Schotten U, et al. [Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)]. Eur. Heart J. 2010;31:2369-429.

Ehrlich JR, Hohnloser SH, Nattel S. [Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence]. Eur. Heart J. 2005;26:2083-92. doi: 10.1093/eurheartj/ehi668

Grundvold I, Skretteberg PT, Lietol K, Erikssen G, et al. [Upper normal blood pressures predict incident atrial fibrillation in healthy middle-age men: a 35-year follow-up study]. Hypertension. 2012;59:198-204. doi: 10.1161/HYPERTENSIONAHA.111.179713

How to Cite

1.
Yalovenko MI, Khaniukov OO. Features of the arterial hypertension clinical course in patients with ischemic heart disease and atrial fibrillation. Med. perspekt. [Internet]. 2019Jan.8 [cited 2024Mar.29];23(4):81-7. Available from: https://journals.uran.ua/index.php/2307-0404/article/view/153005

Issue

Section

CLINICAL MEDICINE